Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
"In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need...Early preclinical studies have shown stress reduction and cognitive improvement," said Silo CEO Eric Weisblum.Silo Pharma Inc (NASDAQ:SILO) shares are trading higher on Tuesday on a high session volume of over 87 million.
Silo Pharma Inc (納斯達克:SILO)股價週二高開，成交量超過8700萬。
The company entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer's drug SPC-14.
該公司進入全球獨家許可協議，進一步開發、製造和商業化其阿爾茨海默病藥物SPC-14。
Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs.
Silo計劃利用FDA簡化的505(b)(2)途徑進行SPC-14的審批，這將縮短臨床試驗時間並降低藥物研發成本。
"In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need...Early preclinical studies have shown stress reduction and cognitive improvement," said Silo CEO Eric Weisblum.
"在我們看來，SPC-14的獨家許可權賦予了我們實現解決一個巨大臨床需求的潛力……早期的臨床前研究已經顯示出降壓和認知改善的效果。"Silo首席執行官Eric Weisblum說。
Silo Pharma recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Silo Pharma最近宣佈了另一個主打藥物SPC-15的獨家許可協議，該藥是治療壓力誘發情感障礙和創傷後應激障礙的鼻腔治療。
Silo recently submitted a pre-IND briefing package and meeting request for SPC-15 to the FDA earlier this month. The company is currently engaged in the final steps required before submission of an IND application to the FDA to begin first-in-human clinical studies.
本月早些時候，Silo公司向FDA提交了SPC-15的預IND簡介包和會議請求。公司目前正在完成提交IND申請前需要的最後幾步工作，以開始進行人體第一階段的臨床研究。
The global Alzheimer's disease therapeutics market is forecasted to exceed $30.8 billion by 2033, with a CAGR of 18.8% from 2024 to 2033.
全球阿爾茨海默病治療市場預計到2033年將達到308億美元，2024年至2033年的年複合增長率爲18.8%。
SPC-14 targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer's disease.
SPC-14針對穀氨酸受體NDMAR和5-羥色胺4型受體5HT4治療阿爾茨海默病的認知和神經精神症狀。
In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.
在最新的小動物臨床前研究中，SPC-14對LH（黃體生成素）應激在減輕學會無助，固執行爲和低新陳代謝方面顯著有效，這是一種衡量焦慮症狀的方法。
Price Action: SILO shares are up 128% at $2.44 at last check Tuesday.
股票價格:SILO股價最近查看週二漲了128%，爲2.44美元。
Photo via Shutterstock
圖片來自shutterstock。